Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

If sucker punched, MNTA must learn to not let that happen again.

They better look at every patent they have, and cover any uncovered areas based on what is going on and likely to go on from here on out. It is obvious how the future generic products will need to cover every base. This will drive the cost up on generics. Bet that.

I am guessing they had to know a couple of weeks ago they were going to take the position they are taking. The question is did they tell MNTA?

MNTA now on notice with Copaxone and any other approvals. Need to think more about any wording on contracts due how they play games on how competition is going to try and avoid patents.

Damages are now wide open to the sky against the 3 defendant's if, they infringed, and now try and sell the product.

Good lesson to learn before any FOB contracts.